Life Science News

Funding to Take Lead Compound Through to Product Approval and Development of Pipeline Assets

F2G Ltd, the UK-based antifungal drug discovery and development company, today announced that it has raised $60 million in financing to develop its pipeline of novel therapies to treat life threatening invasive fungal infections. The round was led by Sectoral Asset Management, with participation from Novo A/S, Aisling Capital and Brace Pharma Capital. Existing investors Advent Life Sciences LLP, Novartis Venture Fund, Sunstone Capital and Merifin Capital each participated in the round.


Sunstone Life Sciences Fund II portfolio company Orphazyme has received a “Study May Proceed” letter from the FDA on Orphazyme’s protocol for arimoclomol as a new treatment for Niemann-Pick disease type C (NP-C), the AIDNPC intervention study. This makes the US Investigational New Drug Application (IND) effective, complementing the corresponding European Clinical Trial Application (CTA) submitted for the same protocol.

Orphazyme runs an international, multi-centre, double-blind intervention study enrolling approximately 46 NP-C patients to be treated with three daily oral doses of arimoclomol or placebo. The objective of the study is to determine the efficacy and safety of arimoclomol in the treatment of NP-C.

Sunstone Life Science Fund I portfolio company Zealand announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration (FDA) has discussed lixisenatide and  iGlarLixi for the treatment of adults with type 2 diabetes. Following the discussions, the Advisory Committee members voted 12 to 2 (with 1 non-vote) to recommend approval of the New Drug Application (NDA) for iGlarLixi in the US. The Advisory Committee was not asked by the FDA to vote on the approval of the NDA for lixisenatide.

Sunstone Life Sciences Fund II portfolio company Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life-science industry”. This is yet another confirmation of Alligator´s success in the field. Alligator is a privately held Swedish biotech company with a pipeline of immune-activating antibodies for tumor-directed immunotherapy of cancer. Notably, in 2015 Alligator granted Janssen Biotech Inc, one of the Janssen Pharmaceutical companies of Johnson & Johnson, an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013. Under the agreement Alligator receives an initial up-front payment and aggregated future milestones up to a potential total of 700 MUSD.

Sunstone LSV Fund II portfolio company VAXIMM AG, a Swiss-German biotech company focused on developing oral T-cell immunotherapies, today announced the appointment of Dr Jarl Ulf Jungnelius, MD, PhD to the newly created position of Chief Medical Officer.

Dr Jungnelius is a seasoned healthcare professional, having spent over thirty years practicing medicine and leading key drug development projects for international pharmaceutical companies, with a strong focus on oncology.